Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01440166 · ClinicalTrials.gov registry record · Phase 1

Safety, Tolerability, and Pharmacokinetic Study of CAT-1004 in Healthy Adult Volunteers

A Phase 1 study of Healthy, sponsored by Catabasis Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
52
Enrollment target
1
Study location

NCT01440166 is a Phase 1 study of Healthy that has completed, run by Catabasis Pharmaceuticals. The registered enrollment target is 52 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01440166, a Phase 1 study of Healthy, has completed, sponsored by Catabasis Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
52 participants
Enrollment target
1
Study location

Study Summary

* To evaluate the safety and tolerability of escalating single doses of CAT-1004 relative to placebo in healthy adult volunteers. * To evaluate the pharmacokinetics (PK) of escalating single doses of CAT-1004 in healthy adult volunteers. * To evaluate the effect of a high-fat meal on single doses of CAT-1004 in healthy adult volunteers.

Conditions Studied

Interventions

  • OTHER Placebo
  • DRUG Drug

Study Locations (1)

Nebraska

  • Celerion Clinical Research Unit - Lincoln

Trial Details

FieldValue
Enrollment Target 52 participants
Start Date 2011-09
Est. Completion 2012-01
Phase Phase 1

Sponsor

Catabasis Pharmaceuticals

12 total trials

What the Registry Record Tells You About NCT01440166

The ClinicalTrials.gov registry entry for NCT01440166 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (92% lower). The listed sponsor is Catabasis Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01440166 reports 1 study location spanning 1 distinct geographic area - top geographies include Nebraska.

Frequently Asked Questions

What is clinical trial NCT01440166 about?

NCT01440166 is a clinical study titled "Safety, Tolerability, and Pharmacokinetic Study of CAT-1004 in Healthy Adult Volunteers". * To evaluate the safety and tolerability of escalating single doses of CAT-1004 relative to placebo in healthy adult volunteers. * To evaluate the pharmacokinetics (PK) of escalating single doses of CAT-1004 in healthy adult volunteers. * To evaluate the effect of a high-fat meal on single doses of...

What is the current status of trial NCT01440166?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2011-09. Estimated completion is 2012-01.

What conditions does trial NCT01440166 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT01440166?

The interventions under investigation include: Placebo (OTHER), Drug (DRUG).

Who is sponsoring clinical trial NCT01440166?

This trial is sponsored by Catabasis Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01440166 being conducted?

This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.